compound 14 [Schnute et al., 2023]   Click here for help

GtoPdb Ligand ID: 12351

Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: This macrocyclic compound is reported as an inverse agonist of retinoic acid receptor-related orphan receptor C2 (RORC2 or RORγt), which is a receptor isoform that's produced from the nuclear hormone receptor-encoding RORC gene in immune cells [1]. It was designed as an anti-inflammatory agent, for topical application.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 6
Hydrogen bond donors 1
Rotatable bonds 2
Topological polar surface area 78.1
Molecular weight 407.22
XLogP 2.41
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CC(C(=O)N1CCN2C[C@@H]1CCCCCS(=O)(=O)Nc1c(c(C2)ccc1)C)C
Isomeric SMILES CC(C)C(=O)N1CCN2C[C@@H]1CCCCCS(=O)(=O)Nc1cccc(C2)c1C
InChI InChI=1S/C21H33N3O3S/c1-16(2)21(25)24-12-11-23-14-18-8-7-10-20(17(18)3)22-28(26,27)13-6-4-5-9-19(24)15-23/h7-8,10,16,19,22H,4-6,9,11-15H2,1-3H3/t19-/m0/s1
InChI Key GMUUZFVHYAPQEI-IBGZPJMESA-N
Immunopharmacology Comments
RORγt is a nuclear hormone receptor that regulates the expression of pro-inflammatory interleukin-17A (and IL-17F) in T-helper 17 (Th17) cells. Selective inhibition of RORγt's transcriptional activity is targeted as a novel anti-inflammatory mechanism. This small molecule is an alternative approach to the approved anti-IL-17A and IL-17 receptor (IL17RA) monoclonal antibodies that are in clinical use as psoriasis, psoriatic arthritis, and ankylosing spondylitis therapeutics (see the entries for secukinumab, ixekizumab, brodalumab).